Sequenom Inc. entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center to explore the utility of Sequenom’s new liquid biopsy assay to comprehensively profile circulating cell-free tumor DNA in blood to enable serial monitoring and assist with therapy selection in cancer patients.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
